ADMA Biologics Inc vs iShares Gold Trust — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while iShares Gold Trust trades at $82.85. The key difference: iShares Gold Trust is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | IAU | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $101.57 |
52-Week Low | $7.60 | $62.49 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
IAU, the iShares Gold Trust ETF, trades at $82.98 with a 0.57% daily gain amid bullish technical signals from moving averages. The ETF benefits from gold's recent momentum as spot gold reached two-month highs above $4,430/oz following cooling CPI data. While oscillators show bearish signals with RSI at overbought levels, institutional interest remains strong with Deane Retirement Strategies increasing its stake by 36.5% in the latest quarter.
Outlook remains positive as gold gains support from inflation dynamics, geopolitical tensions, and central bank buying. Key risks include potential Fed policy shifts and dollar strength. The 0.25% expense ratio makes IAU attractive for conservative investors seeking gold exposure with lower volatility compared to mining stocks.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →